Table 1.
Demographic summary of the study cohort
| CU—Aβ- | CU—Aβ+ | MCI—Aβ+ | |
|---|---|---|---|
| N (% female) | 259 (56%) | 79 (58%) | 90 (48%) |
| Age | 67 (10) | 73 (9)b | 73 (7)b |
| Years of education | 13 (3) | 12 (4) | 13 (4) |
| MMSE | 29.0 (1.1) | 28.7 (1.3)b | 26.5 (2.3) |
| APOE ε4 (%) | 87 (34%) | 58 (73%)b | 69 (77%)b |
| Tau-positive—accordingly to tau-PET (%)a | 0 | 25 (32%)b | 49 (54%)b |
| Aβ-PET retention in the MRS volume | 0.86 (0.08) | 1.56 (0.33)b | 1.73 (0.39)b |
| Tau-PET retention in the MRS volume | 1.06 (0.10) | 1.12 (0.20)b | 1.23 (0.43)b |
| mIns/tCr in the MRS volume | 0.80 (0.08) | 0.84 (0.09)b | 0.86 (0.11)b |
Values are given as mean (standard deviation).
CU, cognitively unimpaired, MCI, mild cognitive impairment; Aβ+/−, amyloid-β positive/negative according to a previously published cut-off of 0.53 based on Aβ-PET32; MMSE, Mini-Mental State Examination; mIns/tCr, myo-inositol to total creatine ratio.
tau positivity was based on the tau-PET retention in a medial temporal meta-ROI reflecting Braak Stage I–II, using a previously published cut-off of 1.4833
significantly different from the cognitively unimpaired Aβ- group (P < 0.05). See Supplementary Fig. 1 for more details about differences in mIns concentrations across groups. See Supplementary results and Supplementary Fig. 2 for an alternative analysis in which participants were stratified accordingly to Aβ and tau positivity/negativity.